Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis
Table 3
Results for MTX combination therapy as obtained with random-effects network meta-analysis at 24 weeks: TOF 5 mg BID + MTX and TOF 10 mg BID + MTX versus treatment.
Treatment (+ MTX)
ACR20 OR (95% CI)
ACR50 OR (95% CI)
ACR70 OR (95% CI)
Withdrawals due to AEs OR (95% CI)
ACR20 OR (95% CI)
ACR50 OR (95% CI)
ACR70 OR (95% CI)
Withdrawals due to AEs OR (95% CI)
TOF 5 mg BID + MTX versus other treatments
TOF 10 mg BID + MTX versus other treatments
TOF 5 mg BID
NA
NA
NA
NA
1.31 (0.57, 3.02)
1.25 (0.59, 2.65)
1.32 (0.74, 2.21)
0.79 (0.41, 1.70)
TOF 10 mg BID
0.76 (0.33, 1.76)
0.80 (0.38, 1.71)
0.76 (0.45, 1.36)
1.26 (0.59, 2.46)
NA
NA
NA
NA
GLB 50 mg Q4W
0.81 (0.15, 4.42)
1.00 (0.26, 3.64)
1.32 (0.32, 4.98)
2.84 (0.63, 13.21)
1.07 (0.20, 5.74)
1.26 (0.33, 4.54)
1.73 (0.41, 6.43)
2.25 (0.51, 10.87)
TCZ 8 mg/kg Q4W
0.86 (0.24, 3.07)
0.89 (0.27, 2.87)
0.71 (0.24, 1.91)
0.86 (0.30, 2.47)
1.12 (0.31, 4.04)
1.11 (0.33, 3.60)
0.93 (0.31, 2.49)
0.68 (0.24, 2.09)
CZP 400 mg Q4W
1.08 (0.20, 5.73)
1.27 (0.23, 6.65)
53.28 (2.66, +infty)
1.68 (0.31, 8.22)
1.42 (0.26, 7.47)
1.60 (0.29, 8.32)
70.27 (3.49, +infty)
1.35 (0.25, 6.79)
IFX 3 mg/kg Q8W
1.48 (0.41, 5.22)
1.58 (0.39, 6.53)
1.46 (0.47, 4.31)
0.94 (0.27, 3.14)
1.94 (0.54, 6.85)
1.99 (0.48, 8.03)
1.92 (0.59, 5.51)
0.75 (0.21, 2.58)
ABT 125 mg QW
1.04 (0.27, 3.94)
0.97 (0.28, 3.21)
1.43 (0.52, 3.31)
2.62 (0.83, 8.59)
1.36 (0.35, 5.15)
1.22 (0.35, 4.01)
1.88 (0.66, 4.27)
2.08 (0.68, 7.22)
ABT 10 mg/kg Q4W
1.50 (0.50, 4.44)
1.17 (0.42, 3.26)
1.59 (0.64, 3.50)
1.83 (0.65, 5.15)
1.96 (0.65, 5.80)
1.47 (0.52, 4.04)
2.10 (0.68, 5.84)
1.45 (0.53, 4.30)
ETN 50 mg QW
1.49 (0.40, 5.39)
1.56 (0.47, 5.18)
1.53 (0.56, 3.99)
2.99 (0.45, 17.55)
1.95 (0.53, 7.01)
1.96 (0.59, 6.41)
2.02 (0.72, 5.11)
2.38 (0.37, 14.70)
ETN 25 mg BIW
1.08 (0.27, 1.95)
1.24 (0.30, 4.11)
1.75 (0.54, 4.50)
2.37 (0.59, 7.31)
1.41 (0.35, 5.31)
1.55 (0.37, 5.12)
2.31 (0.68, 5.84)
1.88 (0.50, 6.08)
ADA 40 mg Q2W
0.74 (0.27, 1.95)
0.87 (0.35, 2.03)
1.46 (0.66, 2.76)
1.31 (0.56, 3.23)
0.97 (0.35, 2.55)
1.09 (0.44, 2.54)
1.92 (0.84, 3.60)
1.04 (0.46, 2.75)
PLBO
3.15 (1.39, 7.05)
4.55 (2.11, 9.66)
6.19 (3.15, 12.04)
1.89 (0.86, 3.87)
4.11 (1.82, 9.26)
5.68 (2.65, 11.98)
8.16 (4.04, 15.65)
1.51 (0.71, 3.28)
Comparable; more effective. OR > 1 favors TOF 5 mg; OR < 1 favors TOF 5 mg; OR > 1 favors TOF 10 mg; OR < 1 favors TOF 10 mg.
